Newly Diagnosed Multiple Myeloma Patients with 1q21
Amplification Treated by Autologous Stem Cell Transplantation
Have Shorter Progression-Free Survival Interval

D 2007

Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Petr KUGLÍK, Hana FILKOVÁ, Romana ZAORALOVÁ et. al.

Basic information

Original name

Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval

Name in Czech

Nově diagnostikovaní pacienti s amplifikací 1q21 léčeni autologní transplantací mají kratší progression-free interval

Authors

NĚMEC, Pavel (203 Czech Republic), Henrieta GREŠLIKOVÁ (703 Slovakia), Petr KUGLÍK (203 Czech Republic), Hana FILKOVÁ (203 Czech Republic), Romana ZAORALOVÁ (203 Czech Republic), Vladimíra VRANOVÁ (703 Slovakia), Jana SMEJKALOVÁ (203 Czech Republic), Petra VIDLÁKOVÁ (203 Czech Republic), Alexandra OLTOVÁ (203 Czech Republic) and Roman HÁJEK (203 Czech Republic, guarantor)

Edition

Washington DC, USA, Blood 2007, Vol.110(11) Part 2, p. 263B-263B, 1 pp. 2007

Publisher

American Society of Hematology (ASH)

Other information

Language

English

Type of outcome

Stať ve sborníku

Field of Study

Genetics and molecular biology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 10.896

RIV identification code

RIV/00216224:14110/07:00019204

Organization unit

Faculty of Medicine

ISSN

UT WoS

000251101102050

Keywords in English

Multiple Myeloma; fluorescence in situ hybridisation; 1q21 Amplification; Autologous stem cell transplantation

Abstract

ORIG CZ

V originále

Amplification of chromosome band 1q21 as well as increased expression of CKS1B gene in this area is a frequently mentioned prognostic factor for patients with multiple myeloma (MM). Total 39 newly diagnosed multiple myeloma patients (median age: 56 years) enrolled in Faculty Hospital Brno, Brno, Czech Republic, were examined for 1q21 amplification status. All patients received 4 cycles of vincristine, adriamycin and dexamethasone (VAD) as induction and one course melphalan 200mg/m2 followed by autologous stem cell transplantation (ASCT). The median follow-up from treatment start was 16.1 (range: 2.2-44.0) months. All the "end-point" intervals and treatment responses were assigned by IMWG criteria. Plasma cells were identified by cytoplasmic light-chain immunofluorescence followed by fluorescence in situ hybridisation (cIg-FISH). Amplification of 1q21 (Amp(1q21)) was assigned utilizing labelled BAC clone (RP11-205M9) DNA probe. Cut-off level for Amp(1q21) was established to 10% of total amount of cells with additional signals detected. Amp(1q21) was found in 41% (16/39) patients. Clinical parameters valid for patients with Amp(1q21) versus patients lacking Amp(1q21) were as follows: overall response rate (ORR) achieved 87.5% (14/16) vs. 91.3% (21/23) patients (p=0.404); overall survival (OS) median was 22.4 months vs. not yet reached (p=0.022); time to progression (TTP) median was 16.1 months vs. not yet reached (p=0.010); progression-free survival (PFS) median was 15.6 months vs. 25.2 months (p=0.023) and duration of response (DOR) median was 15.9 months vs. not yet reached (p=0.048). There were found statistical significant difference in all named "end-point" intervals (OS, TTP, PFS and DOR) between patients with/without Amp(1q21) but not in ORR. In conclusion, patients with Amp(1q21) treated by ASCT have significant shorter PFS median (15.6 months) when compared with patients lacking Amp(1q21) with PFS median 25.2 months (p=0.023). This findings is in accordance with previously published work (Chang et al., 2006).

In Czech

Výsledek pojednává o významu amplifikace 1q21 detekované u pacientů s mnohočetným myelomem léčených autologní transplantací kmenových buněk.

Links

LC06027, research and development project

Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)

Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group

MSM0021622415, plan (intention)

Name: Molekulární podstata buněčných a tkáňových regulací

Investor: Ministry of Education, Youth and Sports of the CR, Molecular basis of cell and tissue regulations

NR9317, research and development project

Name: Prognostický význam klonálních chromosomových aberací při použití nových léčebných metod u mnohočetného myelomu

Citovat

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Petr KUGLÍK, Hana FILKOVÁ, Romana ZAORALOVÁ, Vladimíra VRANOVÁ, Jana SMEJKALOVÁ, Petra VIDLÁKOVÁ, Alexandra OLTOVÁ and Roman HÁJEK. Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval. In Blood 2007, Vol.110(11) Part 2. Washington DC, USA: American Society of Hematology (ASH), 2007, p. 263B-263B, 1 pp. ISSN 0006-4971.

@inproceedings{752135,
   author = {Němec, Pavel and Grešliková, Henrieta and Kuglík, Petr and Filková, Hana and Zaoralová, Romana and Vranová, Vladimíra and Smejkalová, Jana and Vidláková, Petra and Oltová, Alexandra and Hájek, Roman},
   address = {Washington DC, USA},
   booktitle = {Blood 2007, Vol.110(11) Part 2},
   keywords = {Multiple Myeloma; fluorescence in situ hybridisation; 1q21 Amplification; Autologous stem cell transplantation},
   language = {eng},
   location = {Washington DC, USA},
   note = {ASH 2007},
   pages = {263B-263B},
   publisher = {American Society of Hematology (ASH)},
   title = {Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval},
   url = {http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/4758?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=nemec&searchid=1&FIRSTINDEX=0&volume=110&issue=11&resourcetype=HWCIT},
   year = {2007}
}

TY  - JOUR
ID  - 752135
AU  - Němec, Pavel - Grešliková, Henrieta - Kuglík, Petr - Filková, Hana - Zaoralová, Romana - Vranová, Vladimíra - Smejkalová, Jana - Vidláková, Petra - Oltová, Alexandra - Hájek, Roman
PY  - 2007
TI  - Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval
PB  - American Society of Hematology (ASH)
CY  - Washington DC, USA
N1  - ASH 2007
KW  - Multiple Myeloma
KW  - fluorescence in situ hybridisation
KW  - 1q21 Amplification
KW  - Autologous stem cell transplantation
UR  - http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;110/11/4758?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=nemec&searchid=1&FIRSTINDEX=0&volume=110&issue=11&resourcetype=HWCIT
N2  - Amplification of chromosome band 1q21 as well as increased expression of CKS1B gene in this area is a frequently mentioned prognostic factor for patients with multiple myeloma (MM). Total 39 newly diagnosed multiple myeloma patients (median age: 56 years) enrolled in Faculty Hospital Brno, Brno, Czech Republic, were examined for 1q21 amplification status. All patients received 4 cycles of vincristine, adriamycin and dexamethasone (VAD) as induction and one course melphalan 200mg/m2 followed by autologous stem cell transplantation (ASCT). The median follow-up from treatment start was 16.1 (range: 2.2-44.0) months. All the "end-point" intervals and treatment responses were assigned by IMWG criteria. Plasma cells were identified by cytoplasmic light-chain immunofluorescence followed by fluorescence in situ hybridisation (cIg-FISH). Amplification of 1q21 (Amp(1q21)) was assigned utilizing labelled BAC clone (RP11-205M9) DNA probe. Cut-off level for Amp(1q21) was established to 10% of total amount of cells with additional signals detected. Amp(1q21) was found in 41% (16/39) patients. Clinical parameters valid for patients with Amp(1q21) versus patients lacking Amp(1q21) were as follows: overall response rate (ORR) achieved 87.5% (14/16) vs. 91.3% (21/23) patients (p=0.404); overall survival (OS) median was 22.4 months vs. not yet reached (p=0.022); time to progression (TTP) median was 16.1 months vs. not yet reached (p=0.010); progression-free survival (PFS) median was 15.6 months vs. 25.2 months (p=0.023) and duration of response (DOR) median was 15.9 months vs. not yet reached (p=0.048). There were found statistical significant difference in all named "end-point" intervals (OS, TTP, PFS and DOR) between patients with/without Amp(1q21) but not in ORR. In conclusion, patients with Amp(1q21) treated by ASCT have significant shorter PFS median (15.6 months) when compared with patients lacking Amp(1q21) with PFS median 25.2 months (p=0.023). This findings is in accordance with previously published work (Chang et al., 2006).
ER  -

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Petr KUGLÍK, Hana FILKOVÁ, Romana ZAORALOVÁ, Vladimíra VRANOVÁ, Jana SMEJKALOVÁ, Petra VIDLÁKOVÁ, Alexandra OLTOVÁ and Roman HÁJEK. Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval. In \textit{Blood 2007, Vol.110(11) Part 2}. Washington DC, USA: American Society of Hematology (ASH), 2007, p.~263B-263B, 1 pp. ISSN~0006-4971.

Detailed Information on Publication Record